:

Dror Ben Ephraim Noyman1, Clara C Chan2, Joshua C Teichman2

  • 1Ophthalmology Department, Rambam Health Care Campus, Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

PubMed
概括

像TearCare这样的先进治疗方法与梅博米腺表达和强烈脉冲光 (IPL) 显示出对干眼疾病 (DED) 的承诺. 这些疗法为DED症状和梅博米腺功能障碍提供了有效的短期缓解.